Access : Molecular imaging as a de-risking tool: coming into focus? ( vintafolide)

Abstract

Nature Reviews Drug Discovery 12, 251-252 (April 2013) | 

Molecular imaging as a de-risking tool: coming into focus?

Asher Mullard

Abstract

When Endocyte and Merck & Co. asked for European approval for vintafolide in ovarian cancer late last year, the submission package included a novel feature: a molecular imaging companion diagnostic.

To read this article in full you may need to log in, make a payment or gain access through a site license